Loading...
Back to narrative

Update shared on10 Aug 2025

Fair value Increased 11%
AnalystConsensusTarget's Fair Value
US$4.54
16.0% undervalued intrinsic discount
28 Aug
US$3.81
Loading
1Y
-17.5%
7D
-2.6%

The consensus analyst price target for Definitive Healthcare has increased as the company’s future P/E ratio jumped significantly despite a sharp decline in net profit margin, raising fair value from $4.10 to $4.37.


What's in the News


  • Provided Q3 2025 revenue guidance of $59.0–$60.0 million.
  • Raised full-year 2025 revenue guidance to $237.0–$240.0 million, increasing the bottom end by $3.0 million.

Valuation Changes


Summary of Valuation Changes for Definitive Healthcare

  • The Consensus Analyst Price Target has risen from $4.10 to $4.37.
  • The Future P/E for Definitive Healthcare has significantly risen from 4.98x to 22.44x.
  • The Net Profit Margin for Definitive Healthcare has significantly fallen from 51.31% to 8.59%.

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.